These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3063290)

  • 1. Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Sörensen OH; Ljunghall S
    Am J Hypertens; 1988 Oct; 1(4 Pt 1):397-402. PubMed ID: 3063290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol).
    Lind L; Wengle B; Lithell H; Ljunghall S
    J Intern Med; 1992 Apr; 231(4):427-32. PubMed ID: 1588270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Ljunghall S
    Am J Hypertens; 1989 Jan; 2(1):20-5. PubMed ID: 2643969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.
    Lind L; Wengle B; Sørensen OH; Wide L; Akerström G; Ljunghall S
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):250-6. PubMed ID: 2644746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study.
    Lind L; Wengle B; Ljunghall S
    Acta Med Scand; 1987; 222(5):423-7. PubMed ID: 3321926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance.
    Lind L; Lithell H; Skarfors E; Wide L; Ljunghall S
    Acta Med Scand; 1988; 223(3):211-7. PubMed ID: 3281411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No major metabolic alterations accompany the hypotensive effect of active vitamin D.
    Lind L; Wengle B; Lithell H; Ljunghall S
    Ups J Med Sci; 1991; 96(3):199-204. PubMed ID: 1810079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia.
    Joborn C; Hetta J; Lind L; Rastad J; Akerström G; Ljunghall S
    Surgery; 1989 Jan; 105(1):72-8. PubMed ID: 2911806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals.
    Lind L; Wengle B; Lithell H; Ljunghall S
    Scand J Urol Nephrol; 1991; 25(3):233-6. PubMed ID: 1947853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of 1,25-(OH)2-vitamin D are not altered by long-term supplementation with alphacalcidol (1-OH-vitamin D3). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Sörensen OH; Ljunghall S
    Exp Clin Endocrinol; 1992; 99(3):151-3. PubMed ID: 1526265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.
    Rostaing L; Moreau-Gaudry X; Baron E; Cisterne JM; Monroziès-Bernadet P; Durand D
    Clin Nephrol; 1997 Apr; 47(4):248-55. PubMed ID: 9128792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension in primary hyperparathyroidism in relation to histopathology.
    Lind L; Hvarfner A; Palmér M; Grimelius L; Akerström G; Ljunghall S
    Eur J Surg; 1991 Aug; 157(8):457-9. PubMed ID: 1681931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Normocalcemic primary hyperparathyroidism].
    Spivacow FR; Sapag Durán A; Zanchetta MB
    Medicina (B Aires); 2014; 74(6):457-61. PubMed ID: 25555006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population.
    Pierreux J; Bravenboer B
    Horm Metab Res; 2018 Nov; 50(11):797-802. PubMed ID: 30396209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normocalcemic hyperparathyroidism in Vietnamese immigrants living in southern California.
    Luong KV; Nguyen LT
    Am J Med Sci; 2000 Jun; 319(6):380-4. PubMed ID: 10875294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. A pilot study.
    Lind L; Wengle B; Wide L; Wrege U; Ljunghall S
    Nephron; 1988; 48(4):296-9. PubMed ID: 3362275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular calcium and blood pressure: comparison between primary hyperparathyroidism and essential hypertension.
    Fardella C; Rodriguez-Portales JA
    J Endocrinol Invest; 1995 Dec; 18(11):827-32. PubMed ID: 8778153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.